Maryland Capital Management’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

Maryland Capital Management’s Portfolio XBI Stock Details XBI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-5,465	Closed	-$491K	–	252
2022 Q1	$491K	Buy	5,465 +45	+0.8%	+$4.16K	0.03%	164
2021 Q4	$607K	Hold	5,420	–	–	0.03%	151
2021 Q3	$681K	Hold	5,420	–	–	0.04%	141
2021 Q2	$734K	Hold	5,420	–	–	0.04%	136
2021 Q1	$735K	Sell	5,420 -135	-2%	-$20.2K	0.05%	131
2020 Q4	$782K	Hold	5,555	–	–	0.06%	118
2020 Q3	$619K	Hold	5,555	–	–	0.05%	123
2020 Q2	$622K	Buy	5,555 +600	+12%	+$59.1K	0.06%	118
2020 Q1	$384K	Buy	+4,955	New	+$439K	0.05%	149

Other funds holding XBI

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return

Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $69.7B AUM 40.86% 1-Year Est. Return

Clal Insurance Tel-Aviv, Israel $16.6B AUM 68.34% 1-Year Est. Return

APM

Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return

HIIFS

Harel Insurance Investments & Financial Services Ramat Gan, Israel $20.6B AUM 59.59% 1-Year Est. Return

Maryland Capital Management's XBI Position: Q2 2022 in Review

Maryland Capital Management sold out of State Street SPDR S&P Biotech ETF (XBI) in Q2 2022, closing a stake of 5,465 shares — an estimated $491K sold.

Maryland Capital Management first reported a position in XBI in Q1 2020 and held it in 9 quarters. The position peaked at $782K in Q4 2020. 706 funds tracked by Wall St. Rank hold XBI as of Q2 2022.

Maryland Capital Management reported no remaining State Street SPDR S&P Biotech ETF position as of Q2 2022 after selling out during the quarter.
Maryland Capital Management sold 5,465 State Street SPDR S&P Biotech ETF shares in Q2 2022, an estimated $491K.
Maryland Capital Management first reported a position in State Street SPDR S&P Biotech ETF in Q1 2020 and held it in 9 quarters.
Maryland Capital Management's State Street SPDR S&P Biotech ETF position peaked at $782K in Q4 2020.
706 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q2 2022.

Based on Maryland Capital Management's 13F filing for Q2 2022, filed 11 Aug 2022.